Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 141 от 154

Активно (без набиране) Фаза 3

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

Bladder Cancer

A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.

Начало: 13.06.2019 Край: 01.09.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +18 Merck Sharp & Dohme LLC NCT03924856

Активно (без набиране) Фаза 1/2

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Medullary Thyroid Cancer Infantile Myofibromatosis Infantile Fibrosarcoma Papillary Thyroid Cancer +1

This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.

Начало: 13.06.2019 Край: 01.05.2029 Възраст: 6–21 г. Лечение

Australia, Canada, Denmark +7 Eli Lilly and Company NCT03899792

Активно (без набиране) Фаза 2

An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia

Achondroplasia

This is a Phase 2, open-label multi-center long-term extension study, with approximately 70 subjects, to evaluate the safety and efficacy of BMN111 in children with Achondroplasia until subjects reach near-adult final height. Eligible subjects will have completed 1 year of BMN111 or placebo treatment in the 111-206 study and once enrolled in the 111-208 extension study will receive a daily dose of BMN111 by subcutaneous injection according to their age as determined by 111-206.

Начало: 12.06.2019 Край: 01.05.2038 Възраст: от 15 г. Лечение

Australia, Japan, United Kingdom +1 BioMarin Pharmaceutical NCT03989947

Активно (без набиране)

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)

Dermatitis Atopic

Primary Objective: To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant treatments of AD Secondary Objectives: * To characterize real-world use patterns of Dupixent® for AD (eg, used regimens, reason for initiation of new treatments, concomitant therapies, treatment durations and reasons for discontinuation and/or switching) * To assess the long-term effectiveness of Dupixent® in AD patients in a real-world setting * To assess comorbid atopic conditions and effects of treatment in comorbid atopic conditions in patients who receive Dupixent® for AD * To collect safety data on study participants

Начало: 11.06.2019 Край: 31.03.2027 Възраст: от 12 г.

Argentina, Australia, Belgium +18 Sanofi NCT03992417

Активно (без набиране) Фаза 3

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Prostatic Neoplasms

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS) as compared to placebo plus ADT.

Начало: 11.06.2019 Край: 13.10.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +15 Janssen Research & Development, LLC NCT03767244

Активно (без набиране) Фаза 3

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma

The primary objective of the study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and radiation therapy (RT). The secondary objectives of the study are: * To compare the overall survival (OS) of high-risk CSCC patients treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and RT * To compare the effect of adjuvant cemiplimab with that of placebo on patients' freedom from locoregional recurrence (FFLRR) after surgery and RT * To compare the effect of adjuvant cemiplimab with that of placebo on patients' freedom from distant recurrence (FFDR) after surgery and RT * To compare the effect of adjuvant cemiplimab with that of placebo on the cumulative incidence of second primary CSCC tumors (SPTs) after surgery and RT * To evaluate the safety of adjuvant cemiplimab and that of placebo in high-risk CSCC patients after surgery and RT * To assess cemiplimab pharmacokinetics and immunogenicity in human serum

Начало: 04.06.2019 Край: 07.01.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +13 Regeneron Pharmaceuticals NCT03969004

Активно (без набиране) Фаза 1

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Cancer Advanced Solid Tumors Triple-Negative Breast Cancer (TNBC) Non-small-cell-lung-cancer (NSCLC) +1

A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase. The dose-expansion phase can begin once the recommended phase 2 dose/maximum tolerated dose (RP2D/MTD) is determined in the dose-escalation phase.

Начало: 21.05.2019 Край: 01.03.2026 Възраст: от 18 г. Лечение

Australia, France, Israel +3 AbbVie NCT03893955

Активно (без набиране) Фаза 1

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

T-cell Lymphoma

This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug.

Начало: 03.05.2019 Край: 30.04.2026 Възраст: от 18 г. Лечение

Australia, China, South Korea +1 Corvus Pharmaceuticals, Inc. NCT03952078

Активно (без набиране)

PROSpect: Prone and Oscillation Pediatric Clinical Trial

Acute Respiratory Distress Syndrome in Children

Severe pediatric acute respiratory distress syndrome (PARDS) is a life-threatening and frequent problem experienced by thousands of children each year. Little evidence supports current supportive practices during their critical illness. The overall objective of this study is to identify the best positional and/or ventilation practice that leads to improved patient outcomes in these critically ill children. We hypothesize that children with high moderate-severe PARDS treated with either prone positioning or high-frequency oscillatory ventilation (HFOV) will demonstrate more days off the ventilator when compared to children treated with supine positioning or conventional mechanical ventilation (CMV).

Начало: 01.05.2019 Край: 31.01.2027 Възраст: 2–20 г. Лечение

Argentina, Australia, Brazil +12 University of Pennsylvania NCT03896763

Активно (без набиране) Фаза 1

Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

Pediatric Solid Tumor Pediatric Lymphoma Pediatric Brain Tumor DIPG +4

The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.

Начало: 30.04.2019 Край: 25.02.2027 Възраст: 2–25 г. Лечение

Australia, Canada, United States Cellectar Biosciences, Inc. NCT03478462

Активно (без набиране) Фаза 3

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

Hepatocellular Carcinoma

A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.

Начало: 29.04.2019 Край: 31.05.2027 Възраст: 18–150 г. Лечение

Australia, Brazil, Canada +20 AstraZeneca NCT03847428

Активно (без набиране)

Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)

Dermatitis Atopic

Primary Objective: To explore associations between biomarkers of atopic dermatitis (AD) and: * Disease state and time course of AD, * Disease state and evolution of selected atopic comorbid conditions, * Effectiveness of specific AD treatments.

Начало: 05.04.2019 Край: 30.09.2026 Възраст: до 11 г.

Argentina, Australia, Brazil +6 Sanofi NCT03849716

Активно (без набиране) Фаза 3

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

NASH - Nonalcoholic Steatohepatitis

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease

Начало: 28.03.2019 Край: 01.01.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +12 Madrigal Pharmaceuticals, Inc. NCT03900429

Активно (без набиране) Фаза 3

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

Early Alzheimer's Disease

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This study will also evaluate the long-term safety and tolerability of lecanemab in participants with EAD in the Extension Phase and whether the long-term effects of lecanemab as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase. Extension Phase Part B will continue dosing with lecanemab in countries where lecanemab may not be commercially available.

Начало: 27.03.2019 Край: 30.06.2029 Възраст: 50–90 г. Лечение

Australia, Canada, China +11 Eisai Inc. NCT03887455

Активно (без набиране) Фаза 3

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

Open-Angle Glaucoma Ocular Hypertension

This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study (MED-MA-EYE-0648) and completed (or exited early from) the study.

Начало: 27.03.2019 Край: 01.08.2026 Възраст: от 18 г. Лечение

Argentina, Belgium, Brazil +22 AbbVie NCT03891446

Активно (без набиране) Фаза 3

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

Psoriatic Arthritis

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).

Начало: 25.03.2019 Край: 28.09.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +34 AbbVie NCT03675308

Активно (без набиране) Фаза 3

Avelumab Program Rollover Study

Solid Tumors

The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.

Начало: 22.03.2019 Край: 21.08.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +19 EMD Serono Research & Development Institute, Inc. NCT03815643

Активно (без набиране) Фаза 3

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

Metastatic Colorectal Cancer

The main purpose of this study is to demonstrate the superiority of S 95005 in combination with bevacizumab over capecitabine in combination with bevacizumab.

Начало: 21.03.2019 Край: 31.12.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +19 Institut de Recherches Internationales Servier NCT03869892

Активно (без набиране) Фаза 1

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Neoplasm Malignant Renal Cell Carcinoma Hormone Receptor Positive Breast Carcinoma Metastatic Castration-resistant Prostate Cancer +1

This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.

Начало: 20.03.2019 Край: 31.05.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Czechia +7 Exelixis NCT03845166

Активно (без набиране) Фаза 2

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

Pancreatic Cancer Metastatic Pancreatic Cancer Metastatic Pancreatic Adenocarcinoma

Zolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer have a protein called Claudin 18.2 (CLDN18.2) in their tumor. Zolbetuximab is thought to work by attaching to CLDN 18.2 in their tumor. This switches on the body's immune system to attack the tumor. Zolbetuximab is a potential treatment for people with pancreatic cancer. There is an unmet medical need to treat people with pancreatic cancer. This study will help find the dose of zolbetuximab to be used with chemotherapy and provide more information on this treatment in adults with metastatic pancreatic cancer. The study is currently ongoing globally. People in this study will be treated with either zolbetuximab and chemotherapy or chemotherapy by itself. The study's main aims are to find a suitable dose of zolbetuximab to be used with chemotherapy in the second part of this study, to check if zolbetuximab and chemotherapy compared to chemotherapy by itself can improve the survival of people with pancreatic cancer, and to check the safety of zolbetuximab when given with chemotherapy and how well people cope with medical problems during the study. Adults with metastatic pancreatic cancer can take part. Their cancer is metastatic, has the CLDN18.2 marker in a tumor sample and has not previously been treated with chemotherapy. Metastatic means the cancer has spread to other parts of the body. People cannot take part are if they have recently had radiotherapy and have not recovered, need to take medicines to suppress their immune system, have history of nervous system metastases from their pancreatic cancer, or they have other active cancers that need treatment. People who have a specific heart condition or infections also cannot take part. This study will be in 2 parts. Part 1 is called the Safety Lead-in Phase. Groups of people will receive 1 of 2 different doses of zolbetuximab: a lower dose or a higher dose, both together with chemotherapy. A medical expert panel will check the results and decide the dose to use in Part 2. Part 2 is called the Randomization Phase. People will be put in 1 of 2 groups by chance and will be given different treatments either zolbetuximab and chemotherapy or chemotherapy by itself. The chance of receiving zolbetuximab and chemotherapy is twice as high as receiving chemotherapy by itself. In both parts of the study, zolbetuximab and chemotherapy or chemotherapy by itself will be given through a vein. This is called an infusion. Each treatment cycle is 4 weeks (28 days) long and people will have either 2 infusions of zolbetuximab and 3 infusions of chemotherapy or 3 infusions of chemotherapy by itself during each treatment cycle. People will visit the clinic on certain days during their treatment. The study doctors will check for any medical problems from zolbetuximab. Also, people in the study will have a health check including blood tests. On some visits they will also have scans to check for any changes in their cancer. Tumor samples will be taken before treatment if a previous sample is not available. People will have the option of giving a tumor sample after treatment has finished. People will visit the clinic after they stop treatment. They will be asked about any medical problems and will have a health check including blood tests. The number of visits and checks done at each visit will depend on the health of each person and whether they completed their treatment or not.

Начало: 15.03.2019 Край: 31.08.2026 Възраст: от 18 г. Лечение

Australia, Brazil, China +10 Astellas Pharma Global Development, Inc. NCT03816163

1 … 139 140 141 142 143 … 154